Value is a concept that concerns all healthcare stakeholders.
Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.
The focus will now include cardiovascular disease.
The drugmaker known for its massive presence in generics purchased Auspex Pharmaceuticals to bolster its growing specialty business.
Horizon Pharma's purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.
The White House's National Action Plan for Reducing Antibiotic-Resistant Bacteria proposal includes $1.2 billion in funding to reduce superbug infections and develop new diagnostics.
UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals
The duo hope to begin testing a new treatment within three years.
An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.
Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk
The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.
Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute
Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.
Nielsen data shows pharma spent $4.5 billion on DTC ads last year.
Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.
Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases
A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik
An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.
As global healthcare borders become increasingly blurred, the internationally mobile patient may become a standard patient segment considered in healthcare market research.
The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research
Oncology and diabetes medications are expected to be major areas of growth.
At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.
The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.
GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.
Traditional tactics of connecting with physicians are quickly becoming obsolete.
Increased FDA scrutiny has not garnered trust for the new medications.
Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing
The approval follows three advisory panel reviews and a complete response letter.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Lawmakers propose allowing pharma companies to share some off-label information
- US pharma market value projected to be $550 billion in five years
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Apple's ResearchKit: Five Guidelines for Pharma